chantal, Author at Scancell

Notice of Interim Results and Investor Presentation

by chantal | Jan 22, 2026 | Latest News, News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

ESMO IO: Refining Standard of Care in Advanced Melanoma

by chantal | Dec 12, 2025 | Investor Presentations

CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive

by chantal | Dec 12, 2025 | Investor Presentations

European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 10-12 December 2025 in London

by chantal | Dec 10, 2025 | iSCIB1+, SCIB1, Vaccine, Vaccines

Kate Young, Samantha Paston, Heather Shaw, Pippa Corrie, Sarah Danson, Miranda Payne, Poulam Patel, Ioannis Karydis, Satish Kumar, Clare Barlow, Rebecca Lee, Martin Highley, Kellati Prasad, Georgia Goodhew, Gaëlle Cane, Joseph Chadwick, Sabaria Shah, Nermeen Varawalla...

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+

by chantal | Dec 9, 2025 | iSCIB1+, Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

« Older Entries

Next Entries »

Notice of Interim Results and Investor Presentation

ESMO IO: Refining Standard of Care in Advanced Melanoma

CEO Phil L’Huillier gives Report on Melanoma trial success to Proactive

European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 10-12 December 2025 in London

Scancell updated Phase 2 data shows continued improvement in progression free survival with iSCIB1+

Recent Posts

Recent Comments

ACTIVE IMMUNOTHERAPY

ANTIBODIES